Phio Pharmaceuticals Corp. Common Stock

Day range

$0.85 – $0.90

Open

$0.88

Prev close

$0.85

Volume

38.44K

Market cap

$9.9M

Shares out

11.62M

P/E

—

P/S

—

P/B

0.78

P/FCF

—

ROE

-102.4%

ROA

-90.2%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Annual meeting resultsSep 28, 2026

  At the Annual Meeting, the Company's stockholders voted and: (1) elected each of the six directors to serve until the Company's 2027 Annual Meeting of Stockholders; (2) ratified the appointment of Grant Thornton, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026; and (3) approved the Plan Amendment to increase the number of shares of common stock available for issuance under the 2020 Plan by 1,500,000.

• Director appointmentJul 21, 2026

  Effective as of July 20, 2026, the Board of Directors (the "Board") of Phio Pharmaceuticals Corp. (the "Company") increased the size of the Board to six members and appointed R. Todd Plott, M.D. to serve on the Board until the 2026 annual meeting of stockholders. Dr. Plott was also appointed to serve as a member of the Board's Governance Committee. Dr. Plott is a board-certified dermatologist, accomplished researcher, inventor, and former FDA advisory committee member with more than 30 years of experience in dermatologic care and innovation.

• Public offeringApr 8, 2026

  On April 8, 2026, Phio Pharmaceuticals Corp. (the "Company") entered into an At The Market Offering Agreement (the "Sales Agreement") with H.C. Wainwright & Co., LLC, as sales agent (the "Sales Agent"), pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, shares of the Company's common stock, par value $0.0001 per share (the "Shares"). The offering and sale of up to $6,360,000 of the Shares pursuant to the Sales Agreement is being registered under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to the Company's shelf registration statement on Form S-3.

• Executive compensation changeFeb 18, 2026

  The Second Amendment (i) amends the severance provision in the Existing Employment Agreement to provide that, in the event of a termination by the Company without "cause" or by Mr. Bitterman for "good reason", Mr. Bitterman is entitled to severance in the amount of twelve (12) months of his base salary and (ii) provides that Mr. Bitterman's annual target bonus opportunity shall be 50% of his base salary (increased from 40% in the Existing Employment Agreement).

• Clinical trial resultsFeb 10, 2026

  On February 10, 2026, the Company issued a press release announcing the Safety Medical Committee's formal conclusion with respect to the Company's Phase 1b clinical trial of PH-762 and updates with respect to the clinical trial's response rates.

Days to cover

1.0

Short interest

89.45K

Avg volume

114.6K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Merkel Cell Carcinoma Market Set for Rapid Growth in the Coming 10 Years Across the 7MM | DelveInsight
  positiveGlobeNewswire Inc.· Aug 20, 2025
• Phio Posts Wider Loss in Fiscal Q2
  neutralThe Motley Fool· Aug 14, 2025
• Retinoblastoma Treatment Market to Surpass $2 Billion in 2024, Exhibiting a CAGR of 5.5% - Global Long-term Forecasts to 2028 and 2033
  positiveGlobeNewswire Inc.· Aug 23, 2024
• Phio Pharmaceuticals Secures New Investor
  GlobeNewswire Inc.· May 17, 2024
• Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
  GlobeNewswire Inc.· May 15, 2024